GT Biopharma Inc. (NASDAQ: GTBP) announced the implementation of artificial intelligence-based technologies across its drug discovery and engineering programs. The clinical-stage immuno-oncology company said the AI tools are designed to accelerate development of tumor-targeting engagers and multi-domain proteins while reducing costs.

The company uses AI-guided sequence and structural analyses to identify candidate molecules with favorable binding, stability, and developability profiles. The technology also optimizes domain orientation, linker design, and spatial architecture to enhance binding and minimize structural issues that could affect potency or manufacturability.

"We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities," said Michael Breen, Executive Chairman and Chief Executive Officer.

GT Biopharma expects the AI implementation to reduce reliance on trial-and-error experimentation and shorten development timelines. The company anticipates multiple new development candidates will advance to pre-IND development in 2027, with potential targets expanding beyond oncology.

The company currently has GTB-3650 and GTB-5550 advancing through Phase 1 trials. GT Biopharma focuses on developing therapeutics based on its proprietary natural killer cell engager TriKE platform, which is designed to enhance immune system cancer-fighting capabilities.

GT Biopharma operates under an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using TriKE technology. The company is based in San Francisco, California.